Reminder: FDA's FIRST Authorized AI in Any Field of Medicine Was for Diabetic Retinopathy (IDx-DR / LumineticsCore, April 2018)
Strategic context: vision is the bow wave of clinical AI adoption — not radiology, not pathology, not ambient documentation. The FIRST FDA De Novo authorized autonomous AI in the entire history of US medicine was IDx-DR (now LumineticsCore from Digital Diagnostics) in April 2018, for diabetic retinopathy detection in primary care. 87.2% sensitivity / 90.7% specificity. Two more autonomous AI systems followed: EyeArt (Eyenuk, 2020 — 96% sens / 88% spec for mtmDR), and AEYE-DS (AEYE Health, 2022 — 93% / 91.4%, expanded 2024 for handheld portable). Plus SCANLY Home OCT (Notal Vision, May 2024) — first FDA-authorized patient-self-operated home OCT. Cahaba Medical Care (AL FQHC) deployment data: AI identified previously-missed DR in >1-in-4 patients screened. CA documented FQHC adopters: Tarzana Treatment Centers (LumineticsCore), San Ysidro Health (EyeArt RCT).
Primary source
FDAAffected FQHCs
FQHC Talent. (2018, April 11). Reminder: FDA's FIRST Authorized AI in Any Field of Medicine Was for Diabetic Retinopathy (IDx-DR / LumineticsCore, April 2018). Primary source: FDA. Retrieved May 1, 2026, from https://www.fqhctalent.com/intel/fda-first-medical-ai-was-diabetic-retinopathy-2018
More in Strategy & Tactics
Apr 30
Epic's 2026 AI Rollout (Art, Emmie, Penny) Reaches OCHIN — But on a 6-18 Month Lag
Apr 30
Abridge Names FQHC Cohort: AltaMed, El Rio, Yakima Valley Farm Workers, TrueCare
Apr 17
CHCF Brief: Assisted Living as Housing Solution for Californians with Behavioral Health Needs
Apr 15
Ophthalmology Science Names FQHCs as 'Ideal Locations' for Autonomous AI Diabetic Retinopathy Screening — Real-World Adoption Playbook